Published in:
01-03-2016 | Original Article
Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors
Authors:
Viktor Arnhold, Joachim Boos, Claudia Lanvers-Kaminsky
Published in:
Cancer Chemotherapy and Pharmacology
|
Issue 3/2016
Login to get access
Abstract
Purpose
The successful use of SMO inhibitors in tumors with activating mutations in hedgehog signaling raised interests in their exploitation against other malignancies. The role of hedgehog signaling in pediatric malignancies remains unclear.
Methods
We investigated the hedgehog signaling and its inhibition in a panel of 18 tumor cell lines derived from six of the most common and highly aggressive pediatric tumor types. None of the cell lines was known to stem from tumors with activating hedgehog mutations. Tetrazolium-based assays (MTT and MTS) and BrdU assays were used to analyze cell viability and proliferation after exposure to SANT1 and GANT61. Expression analysis of hedgehog signaling members and cyclins was performed by quantitative real-time PCR and Western blot.
Results
Key members of hedgehog signaling (SHH, PTCH1, SMO, GLI1, GLI2 and SUFU) were expressed in all cell lines. In 50 % of the cell lines viability was significantly increased by SHH exposure. Stimulation was not restricted to distinct tumor types, but related to cell lines with higher mRNA levels of PTCH1, SMO, GLI1 and GLI2. SMO inhibition by SANT1 moderately decreased cell viability with GI50s between 28 and 93 µmol/l. Sensitivity to SANT1 was not related to distinct tumor types. The GLI inhibitor GANT61 inhibited cell viability and proliferation more effectively than SANT1.
Conclusions
Our preclinical data provide evidence that hedgehog signaling is active and can be stimulated by PTCH1 ligands in various pediatric tumors. We suggest further evaluation of GLI inhibitors as inhibitors of hedgehog signaling for the treatment of the investigated tumor types.